Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-001 in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
NCT04234048Phase 1Recruiting
- Sponsor
- SciTech Development
- Start
- Dec 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fenretinide in T-cell non-Hodgkin lymphoma, sponsored by SciTech Development. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Dec 2023; status: recruiting.
02
Drugs
fenretinide
03
Conditions
T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04234048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04234048.